421 related articles for article (PubMed ID: 30400777)
1. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).
Murray ML; Meadows J; Doré CJ; Copas AJ; Haddow LJ; Lacey C; Jit M; Soldan K; Bennett K; Tetlow M; Nathan M; Gilson R
BMC Med Res Methodol; 2018 Nov; 18(1):125. PubMed ID: 30400777
[TBL] [Abstract][Full Text] [Related]
2. [Anogenital warts: a new way of solving the common problem of urology (results of long-term follow-up)].
Protasov AD; Lipatov IS; Kostinov MP; Tezikov YV; Shmitko AD; Pakhomov DV; Blagovidov DA; Zhestkov AV; Ryzhov AA; Vekhova EV
Urologiia; 2016 Nov; (5):47-51. PubMed ID: 28248020
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study.
Saiag P; Bauhofer A; Bouscarat F; Aquilina C; Ortonne JP; Dupin N; Mougin C
Br J Dermatol; 2009 Oct; 161(4):904-9. PubMed ID: 19466962
[TBL] [Abstract][Full Text] [Related]
4. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
Edwards L; Ferenczy A; Eron L; Baker D; Owens ML; Fox TL; Hougham AJ; Schmitt KA
Arch Dermatol; 1998 Jan; 134(1):25-30. PubMed ID: 9449906
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts.
Komericki P; Akkilic-Materna M; Strimitzer T; Aberer W
Sex Transm Dis; 2011 Mar; 38(3):216-8. PubMed ID: 20938374
[TBL] [Abstract][Full Text] [Related]
6. Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials.
Werner RN; Westfechtel L; Dressler C; Nast A
Sex Transm Infect; 2017 Dec; 93(8):543-550. PubMed ID: 28637906
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus: burden of illness and treatment cost considerations.
Fox PA; Tung MY
Am J Clin Dermatol; 2005; 6(6):365-81. PubMed ID: 16343025
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic approaches to genital warts.
Beutner KR; Ferenczy A
Am J Med; 1997 May; 102(5A):28-37. PubMed ID: 9217660
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.
Vandepapeliere P; Barrasso R; Meijer CJ; Walboomers JM; Wettendorff M; Stanberry LR; Lacey CJ
J Infect Dis; 2005 Dec; 192(12):2099-107. PubMed ID: 16288373
[TBL] [Abstract][Full Text] [Related]
10. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
11. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study.
Coskuner ER; Ozkan TA; Karakose A; Dillioglugil O; Cevik I
J Sex Med; 2014 Nov; 11(11):2785-91. PubMed ID: 25124237
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation.
Thurgar E; Barton S; Karner C; Edwards SJ
Health Technol Assess; 2016 Mar; 20(24):v-vi, 1-486. PubMed ID: 27034016
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
14. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
Steben M; Ouhoummane N; Rodier C; Sinyavskaya L; Brassard P
J Med Virol; 2018 Mar; 90(3):592-598. PubMed ID: 28980715
[TBL] [Abstract][Full Text] [Related]
15. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
16. [A model-based comparison of cost effectiveness of imiquimod versus podophyllotoxin for the treatment of external anogenital warts in France].
Lafuma A; Monsonego J; Moyal-Barracco M; Pribil C
Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):731-6. PubMed ID: 14576602
[TBL] [Abstract][Full Text] [Related]
17. New approach to managing genital warts.
Lopaschuk CC
Can Fam Physician; 2013 Jul; 59(7):731-6. PubMed ID: 23851535
[TBL] [Abstract][Full Text] [Related]
18. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
19. [Topical imiquimod cream in the treatment of external anogenital warts: personal experience].
Senatori R; Dionisi B; Lippa P; Inghirami P
Minerva Ginecol; 2003 Dec; 55(6):541-6. PubMed ID: 14676745
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.
Sanclemente G; Herrera S; Tyring SK; Rady PL; Zuleta JJ; Correa LA; He Q; Wolff JC
J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1054-60. PubMed ID: 17714124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
